Clinical Trials Directory

Trials / Completed

CompletedNCT03939403

Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor

Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor. A Randomized Clinical Trial. TAIL Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
180 (actual)
Sponsor
Instituto Bernabeu · Academic / Other
Sex
Female
Age
18 Years – 32 Years
Healthy volunteers
Accepted

Summary

This study aims to study the efficiency of using a single injection of Corifollitropin alfa for ovarian stimulation by initiating administration late and without further administration of follicle-stimulating hormone after the 7th day of stimulation compared to conventional ovarian stimulation using Corifollitropin alfa (drug administration 5 days after cessation of hormonal contraceptive and supplementation with follicle-stimulating hormone daily administration from the 8th day of stimulation). This a controlled randomized clinical study and 180 patients will be recruited (90 per arm) and the primary study outcome is the number of obtained oocytes.

Conditions

Interventions

TypeNameDescription
DRUGTime of administration of Corifollitropin AlfaThe used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity. The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity. The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use.

Timeline

Start date
2019-11-18
Primary completion
2021-05-08
Completion
2021-05-08
First posted
2019-05-06
Last updated
2021-05-19

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT03939403. Inclusion in this directory is not an endorsement.